[This corrects the article DOI: 10.3389/fendo.2021.645563.].
Keywords: glucagon-like peptide-1 receptor agonist (GLP-1RA); oral; safety; semaglutide; subcutaneous; type 2 diabetes.
Copyright © 2021 Smits and Van Raalte.